SCHEMBL20138307

SCHEMBL20138307

Cc1ncccc1CN1C(=O)COc2ccc(-c3ccc4c(c3)C(=O)NCC4)nc21

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.42
PARP10 Q53GL7 6/20 0.36
PARP1 P09874 5/20 0.36
BRD4 O60885 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
MET P08581 2/20 0.34
KDM4E B2RXH2 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
PARP11 Q9NR21 2/20 0.32
PRF1 P14222 1/20 0.32
F7 P08709 1/20 0.32
F3 P13726 1/20 0.32
APOBEC3A P31941 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
PDPK1 O15530 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20138109 0.87 MAPK1 (0.43) MAPK1PARP10PARP1BRD4JAK2
SCHEMBL20138313 0.85 MAPK1 (0.41) MAPK1PARP10PARP1METCD274
SCHEMBL20138280 0.85 MAPK1 (0.41) MAPK1PARP10PARP1METCD274
SCHEMBL20137967 0.83 MAPK1 (0.43) MAPK1PARP10PARP1BRD4JAK2
SCHEMBL20138236 0.82 MAPK1 (0.37) MAPK1PARP10PARP1BRD4CD274
SCHEMBL20138284 0.76 TSHR (0.39) MAPK1BRD4APOBEC3AAPOBEC3G
SCHEMBL20137962 0.74 MAPK1 (0.36) MAPK1PARP10PARP1CD274MAPKAPK2
SCHEMBL20138175 0.73 MAPK1 (0.34) MAPK1PARP10PARP1CD274PARP11
SCHEMBL20137915 0.70 MAPK1 (0.41) MAPK1PARP10PARP1BRD4CD274
SCHEMBL20138262 0.70 MAPK1 (0.37) MAPK1PARP10PARP1CD274MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity UCB BIOPHARMA SPRL (BE) 2019-05-14 US disclosed
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity UCB S.A. (BE) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity TNF, NFKBIA, TNFRSF1A MAPK1 1235/4885PARP10 1687/4885PARP1 1553/4885
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity TNF, TNFRSF1A, NFKBIA MAPK1 1268/4885PARP10 3857/4885PARP1 2142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.